AstraZeneca Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de AstraZeneca de 13.7% y 6% por año respectivamente. Se prevé que el BPA crezca en un 14.5% al año. Se espera que la rentabilidad financiera sea de 28.4% en 3 años.
Información clave
13.7%
Tasa de crecimiento de los beneficios
14.54%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 12.2% |
| Tasa de crecimiento de los ingresos | 6.0% |
| Rentabilidad financiera futura | 28.40% |
| Cobertura de analistas | Good |
| Última actualización | 19 Aug 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Aug 13
AZN: Pipeline Strength And 2030 Revenue Ambition Will Drive Re Rating
Analysts have trimmed AstraZeneca's fair value estimate to £189.66 from £200.76, reflecting slightly higher assumed discount rates and more cautious long-term revenue growth expectations, partly informed by recent mixed trial outcomes and Street price target revisions. Analyst Commentary Recent Street commentary on AstraZeneca highlights a mix of caution around specific trial setbacks and corporate scenarios, along with continued confidence in the broader pipeline, execution, and long term growth ambition.
Actualización de narrativa • Jul 30
AZN: Oncology Approvals And Pipeline Progress Will Support Future Repricing
Analysts have trimmed their AstraZeneca price targets, with the modelled fair value easing from £164.85 to £159.11. This reflects slightly lower assumptions for revenue growth, profit margin and future P/E following recent trial setbacks and updated Street research.
Actualización de narrativa • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.Actualización de narrativa • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Artículo de análisis • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...Actualización de narrativa • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.Actualización de narrativa • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.Actualización de narrativa • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.Actualización de narrativa • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.Actualización de narrativa • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.Actualización de narrativa • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.Actualización de narrativa • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.Actualización de narrativa • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.Actualización de narrativa • Feb 03
AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.Actualización de narrativa • Jan 20
AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.Actualización de narrativa • Jan 06
AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 71,269 | 15,668 | 14,461 | 20,691 | 21 |
| 12/31/2027 | 66,838 | 13,716 | 12,972 | 18,841 | 24 |
| 12/31/2026 | 63,248 | 12,070 | 9,418 | 16,496 | 24 |
| 6/30/2026 | 61,366 | 10,446 | 6,250 | 13,700 | N/A |
| 3/31/2026 | 60,439 | 10,389 | 7,919 | 14,221 | N/A |
| 12/31/2025 | 58,739 | 10,225 | 8,806 | 14,575 | N/A |
| 9/30/2025 | 58,127 | 9,399 | 9,679 | 15,140 | N/A |
| 6/30/2025 | 56,501 | 8,295 | 8,327 | 13,389 | N/A |
| 3/31/2025 | 54,982 | 7,772 | 9,195 | 13,088 | N/A |
| 12/31/2024 | 54,073 | 7,035 | 7,398 | 11,861 | N/A |
| 9/30/2024 | 51,206 | 6,495 | 6,867 | 11,334 | N/A |
| 6/30/2024 | 49,133 | 6,440 | 7,045 | 11,065 | N/A |
| 3/31/2024 | 47,611 | 6,331 | 5,887 | 9,698 | N/A |
| 12/31/2023 | 45,811 | 5,955 | 6,858 | 10,345 | N/A |
| 9/30/2023 | 44,994 | 5,896 | 7,270 | 10,363 | N/A |
| 6/30/2023 | 44,485 | 6,163 | 6,854 | 10,179 | N/A |
| 3/31/2023 | 43,840 | 4,705 | 6,357 | 9,709 | N/A |
| 12/31/2022 | 44,351 | 3,288 | 7,684 | 9,808 | N/A |
| 9/30/2022 | 45,155 | 2,040 | 6,538 | 8,828 | N/A |
| 6/30/2022 | 44,038 | -1,253 | 5,789 | 7,617 | N/A |
| 3/31/2022 | 41,487 | -1,063 | 5,721 | 7,261 | N/A |
| 12/31/2021 | 37,417 | 112 | 4,350 | 5,963 | N/A |
| 9/30/2021 | 32,816 | 1,471 | 5,184 | 6,343 | N/A |
| 6/30/2021 | 29,528 | 3,771 | 5,421 | 6,446 | N/A |
| 3/31/2021 | 27,583 | 3,977 | 4,899 | 6,594 | N/A |
| 12/31/2020 | 26,617 | 3,196 | 3,144 | 4,799 | N/A |
| 9/30/2020 | 25,871 | 2,497 | 3,273 | 4,376 | N/A |
| 6/30/2020 | 25,699 | 2,148 | 3,057 | 3,657 | N/A |
| 3/31/2020 | 25,247 | 1,522 | N/A | 3,495 | N/A |
| 12/31/2019 | 24,384 | 1,335 | N/A | 2,969 | N/A |
| 9/30/2019 | 24,137 | 2,056 | N/A | 3,818 | N/A |
| 6/30/2019 | 23,071 | 2,188 | N/A | 3,184 | N/A |
| 3/31/2019 | 22,403 | 2,408 | N/A | 2,371 | N/A |
| 12/31/2018 | 22,090 | 2,155 | N/A | 2,618 | N/A |
| 9/30/2018 | 21,450 | 2,422 | N/A | 1,391 | N/A |
| 6/30/2018 | 22,342 | 2,677 | N/A | 3,165 | N/A |
| 3/31/2018 | 22,238 | 2,804 | N/A | 3,350 | N/A |
| 12/31/2017 | 22,465 | 3,001 | N/A | 3,578 | N/A |
| 9/30/2017 | 22,273 | 3,542 | N/A | 4,541 | N/A |
| 6/30/2017 | 21,740 | 3,870 | N/A | 3,109 | N/A |
| 3/31/2017 | 22,292 | 3,390 | N/A | 3,040 | N/A |
| 12/31/2016 | 23,002 | 3,499 | N/A | 4,145 | N/A |
| 9/30/2016 | 23,816 | 2,465 | N/A | 2,756 | N/A |
| 6/30/2016 | 24,062 | 2,221 | N/A | 3,690 | N/A |
| 3/31/2016 | 24,766 | 2,921 | N/A | 4,589 | N/A |
| 12/31/2015 | 24,708 | 2,825 | N/A | 3,324 | N/A |
| 9/30/2015 | 25,025 | 1,696 | N/A | 4,595 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.7% al año) de AZN es superior a la tasa de ahorro (3.6%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.7% al año) de AZN crezcan más rápidamente que el mercado UK (11.6% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de AZN crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (6% al año) de AZN crezcan más rápidamente que los del mercado UK (3.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6% al año) de AZN crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de AZN sea alta dentro de 3 años (28.4%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/21 07:53 |
| Precio de las acciones al final del día | 2026/08/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AstraZeneca PLC está cubierta por 56 analistas. 24 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |